BioCentury | Jun 20, 2018
Finance

Iterating iTeos

With a new office in the U.S. and $75 million in fresh series B funding to support clinical development of at least two candidates, Belgian cancer company iTeos Therapeutics S.A. is considering a U.S. IPO...
BioCentury | May 18, 2018
Company News

Genentech terminates NewLink collaboration for IDO, TDO inhibitors

...Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Cancer Jaime De Leon Genentech Inc. NewLink Genetics Corp. Indoleamine 2,3-dioxygenase (IDO) (INDO) Tryptophan 2,3-dioxygenase (TDO) (TDO2)...
BioCentury | Oct 26, 2015
Strategy

Collaborating on combos

As oncologists and drug developers converge on the idea that combination therapies built on a backbone of PD-L1 or PD-1 inhibitors could lead to cures for some cancers, or keep them at bay for years,...
Items per page:
1 - 3 of 3